Efficacy and Safety of Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria in Pregnant Women: A Systematic Review and Meta-Analysis

Workineh Shibeshi
Assefa Mulu Baye
Getachew Alemkere
Ephrem Engidawork

Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia

Introduction: Malaria is one of the infectious diseases with substantial risks for pregnant women, the fetus and the newborn child. Thus, prevention and treatment of malaria with safe and effective drugs is of paramount importance. Pregnant women are mostly excluded from clinical trials, and systematic approaches of pharmacovigilance in pregnancy are limited. This means the safety and efficacy of antimalarial agents during pregnancy are unclear.

Purpose: This study was designed to carry out a systematic review and aggregate data meta-analysis of literature published on efficacy and safety of artemisinin-based combination therapy (ACT) for uncomplicated malaria in pregnant women.

Methods: A search of literature published between 1998 to 2020 on efficacy and safety of artemisinin-based combination therapy (ACT) in pregnant women was made using Cochrane Library, Medline and the Malaria in Pregnancy Consortium Library. Data were extracted independently by two reviewers, and any discrepancies were resolved by consensus. Meta-analysis was carried out using Open Meta-Analyst software. Random effects model was applied, and the heterogeneity of studies was evaluated using Higgins I².

Results: Twenty-four studies that fulfilled the inclusion criteria were included in the final assessment. Overall, days 28 to 63 malaria treatment success rate was 96.1%. Overall days 28 to 63 cure rates for AL, AS+AQ, AS+MQ, DHA+PQ, AS+ATQ+PG and AS+SP were 95.1%, 92.2%, 97.0%, 94.3%, 96.5% and 97.4%, respectively. Comparison of ACTs with non-ACTs revealed that the risk of treatment failure was substantially lower in patients treated with ACTs than with non-ACTs (risk ratio 0.20, 95% C.I. 0.09–0.43). The overall prevalences of miscarriage, stillbirth and congenital anomalies were 0.3%, 2.1% and 1.0%, respectively, and found to be comparable among various ACTs. There was comparable tolerability across ACTs during pregnancy.

Conclusion: ACTs demonstrated a high cure rate, safety and tolerability against Plasmodium falciparum infection in pregnant women. The higher treatment success and comparable tolerability could be used as an input for decision makers to support the continued usage of ACTs for treatment of uncomplicated falciparum malaria in pregnant women.

Keywords: efficacy, safety, artemisinin-based combination therapy, uncomplicated malaria, pregnant women, systematic review and meta-analysis

Introduction

Although the global malaria burden has tended to decline with time (238 million in 2000, 231 million in 2017, 229 million cases in 2019); it still remains a significant health problem, particularly in Africa, which is home for the large majority of cases.
Artemisinin-based combination therapy (ACT) is a combination of artemisinin family of drugs and other non-artemisinin partners. Even though both the artemisinin and non-artemisinin components are essential for the antimalarial efficacy, the artemisinin component is vital to decrease parasite density in the early days of treatment. The remaining parasites are cleared by the partner drug. Therefore, the two drugs achieve effective clinical and parasitological cures and it is also believed that using this combination protects each other from development of resistance. The most important challenge in the global fight against malaria is Plasmodium resistance to antimalarial medicines. Regular monitoring of efficacy of antimalarial agents supports early identification of changes in how well the recommended treatments work so as to mitigate any impact of resistance and prevent its spread.

Currently, the World Health Organization (WHO) recommends ACTs for the treatment of uncomplicated malaria in pregnant women in the 2nd or 3rd trimester. Seven days of quinine with clindamycin is recommended for the management of malaria in the first trimester. However, the use of ACTs in the first trimester of pregnancy is recommended if: (i) ACTs are the only treatment option immediately available; (ii) failure occurs after treatment with 7-day quinine plus clindamycin; or (iii) adherence is a challenge with the 7-day treatment.

As evidenced by animal studies, ACT derivatives were found to be embryotoxic and teratogenic. The studies suggested that the critical time period for exposure in humans is in the first trimester. Various organs including uterus, ears, brain and eyes are still in development and growth phase in the second trimester, and are therefore sensitive to exogenous substances that can result in malformations. However, data from animal studies do not always predict the effects observed in humans. Indeed, observational studies and randomized controlled clinical trials (RCTs) did not report increased risk of adverse pregnancy outcomes such as stillbirth or miscarriage after taking artemisinins during pregnancy compared with those taking non-artemisinins as well as those with no antimalarial agents. Periodic evidence synthesis from several clinical and observational studies on therapeutic efficacy and safety of ACTs in pregnant population is required, which may indicate any evolving changes or trends in the clinical use of ACTs. Hence, our study aimed to conduct a systematic review and meta-analysis, and to generate comprehensive evidence on the efficacy and risk of adverse pregnancy outcomes associated with the use of ACTs during pregnancy.

**Methods**

**Eligibility Criteria**

Eligible studies for this review were interventional, observational cohort and pharmacokinetic studies enrolling pregnant women at first, second and third trimesters of pregnancy and receiving an ACT with or without comparative arm interventions for the treatment of uncomplicated Plasmodium falciparum or Plasmodium vivax mono-infections. Only published articles in English were included. Studies on non-pregnant adults and pediatrics, not involving artemisinins treatment or using artemisinin monotherapy, on malaria prevention or prophylaxis, and that did not report either efficacy or pregnancy safety outcomes were excluded.

**Search Strategy**

A literature search was performed to identify articles that included safety and efficacy outcomes of ACT exposure during pregnancy. The electronic search was carried out on February 28, 2020 through the Cochrane Library, Medline and Malaria in Pregnancy Consortium Library using keywords and MeSH terms with no restriction for time of publication. The search followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines (S1 Table). The search terms consisted of (Pregnant women OR pregnant* AND malaria) AND (Artemisinin* OR artemisinin combination therapy OR ACT OR artemether OR artemether OR dihydroartemisinin OR artemether OR artesunate OR dihydroartemisinin OR artemether OR artemether OR dihydroartemisinin OR artemether).
abnormalities OR congenital malformations OR congenital anomalies).

Data Extraction
Decision to select a retrieved article was made by two reviewers (AM and GA) who worked independently through screening of titles and abstracts followed by full text assessment. A data abstraction format was used for screening purposes and an article is selected when there is an agreement between the two reviewers. Any disagreements were resolved by discussion and consensus. Data related to author(s) of the articles, year of publication, year the studies were conducted, geographic location of the study, duration of the study, trimester of pregnancy, age, weight, parity and gravidity of participants, type of malaria species, baseline parasite density and temperature, and type of study design (observational, intervention) were extracted from each article. Data regarding the types of malaria treatment agents, treatment duration, treatment outcome measures, pregnancy outcome (miscarriage, stillbirth, birth weight, intrauterine growth retardation rate, gestational age and prematurity) and other adverse events including laboratory abnormalities were also extracted and included in the systematic review and meta-analysis.

Quality Assessment
The two reviewers independently assessed methodological quality of studies using revised tool for assessing risk of bias in randomized trials (ROB 2)18 for RCTs and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for observational studies.19 The observational studies were categorized as high quality (over 75% of the STROBE checklist) and low quality (under 75% of the STROBE checklist). The quality of the included clinical trials was assessed and quality was categorized as “low risk of bias”, “some concerns” or “high risk of bias”.

Outcome Definitions
Days 28 to 63 (whichever was reported latest) PCR-corrected adequate clinical and parasitological response (ACPR) was taken as primary outcome of efficacy for the meta-analysis. ACPR was defined as absence of parasitemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of early treatment failure or late clinical failure or late parasitological failure.20 The primary outcomes for safety included mean birth weight and gestational age as well as prevalence of low birth weight, prematurity, congenital abnormalities, stillbirth, and miscarriage. To evaluate tolerability, we assessed the prevalence of adverse effects, including tinnitus, asthesia, dizziness, poor appetite, nausea, and vomiting.

Statistical Methods
The meta-analysis of malaria treatment efficacy was performed by OpenMeta Analyst software for Windows.21 Cochrane Q and the I² statistic were employed to evaluate heterogeneity of the included studies. Cochrane Q with P < 0.10 and I² > 50 were taken as standard to indicate the presence of heterogeneity of the included studies.22 P < 0.05 was used to declare statistical significance.

Results
Study Characteristics
Out of 1108 studies identified, 89 were included for review of the full text. Of these, 24 studies met the inclusion criteria (Figure 1). Studies based on the same cohort were considered as a single study. As indicated in Table 1, 18 studies were from sub-Saharan Africa, including 3 studies from Nigeria,23-25 2 studies from Tanzania,26,27 2 studies each from Sudan28,29 and Uganda,10,30 1 study each from Sudan.30,31 Congo,32 Ghana,33 Malawi,34 and Rwanda.11 One study was reported from four African countries (Burkina Faso, Ghana, Malawi, Zambia, Congo).35 The outcome of pregnancy and infant mortality from this study was reported separately.36 As part of the study from the four African countries,35 the output from Zambia was reported separately.37 The other 8 studies were from Asia; one from India38 and one from the Thai-Myanmar border39 and six studies from Thailand.13-15,40-42

The studies were conducted between May 1986 and April 2015 but published between 1998 and February 2020. Sixteen of the studies were clinical trials (one double blind and 15 open-label, all were RCTs but one), 7 were prospective observational studies, two studies one of which is part of a clinical trial,43 were pharmacokinetic studies and the remaining was a single arm study29 (Table 2). By type of malaria infection, 25 studies involved falciparum malaria, but two observational studies involved both falciparum and vivax malaria infections.13,39

ACTs used in the trials include artemether-lumefantrine (15 studies), amodiaquine-artesunate (7 studies),
mefloquine-artesunate (8 studies), sulfadoxine-pyrimethamine (SP-artesunate (4 studies), atovaquone-proguanil-artesunate (2 studies), artemether-mefloquine (1 study), artemether-lumefantrine with quinine (1 study), dihydroartemisinin + piperaquine (4 studies) and unspecified artemisinin derivative (1 study).

In most of the studies, durations of ACTs were 3 days. But there were exceptions, where 5 days of artemether injection and artemether-lumefantrine combination therapy was used in Nigeria and Congo, respectively, as well as 7 days of artesunate therapy in Thailand.

Other antimalarial drugs used in the studies included quinine (5 studies), SP (3 studies), mefloquine (2 studies), SP in combination with azithromycin (1 study), SP with amodiaquine (1 study), amodiaquine (1 study), chloroquine (1 study), atovaquone with proguanil (1 study) and chlorproguanil and dapsone (CD) (2 studies). Detailed description of studies included in this systematic review and meta-analysis is indicated in a supplementary file (S2 Table).

Characteristics of the Study Participants
A total of 9482 pregnant women were exposed to antimalarial agents, with the majority (6860, 72.3%) of them exposed in the 2nd or 3rd trimester, and 2622 (27.7%) in the first trimester. In addition, 2482 pregnant women were unexposed controls in the 24 studies but included for comparison purpose. In one of these studies, 30 healthy non-pregnant women were included as comparators. Twenty-four non-pregnant women on AS+MQ were also compared with pregnant women.

A total of 6600 women in the 24 studies received ACT during the first, second and third trimesters of pregnancy (Tables 1 and 2). The most common ACT exposures were:
**Table 1** Description of the Studies Identified in the Systematic Review and Meta-Analysis of Safety and Efficacy of Artemisinin-Based Therapy in Pregnant Women

| Author, Year | Country                  | Study Design       | Treatment                                                                 | N    |
|--------------|--------------------------|--------------------|----------------------------------------------------------------------------|------|
| Sowunmi 1998 | Nigeria                  | Open-label RCT     | AM IM (3.2 mg/kg at day 0, then 1.6 mg/kg daily from day-1 to day-4) AM+MQ (artemether 3.2 mg/kg at day 0, 7.5 mg/kg mefloquine at day-1 and day-2) | 23   |
| Adam 2006    | Sudan                    | Single arm study   | AS+SP (two tablets of 100 mg artesunate on days 0–2 and three tablets of SP (500/25 mg) given as a single dose on day 0. | 32   |
| Adam 2009    | Sudan                    | Prospective follow-up | AM inj., AS+SP or AL                                      | 62   |
| Anvikar 2018 | India                    | Open-label RCT     | AS+SP (artesunate 200 mg daily for 3 days and SP 1500/75 mg on day one) AS+MQ (200/440 mg daily for 3 days) | 125  |
| Kaye 2008    | Uganda                   | Open-label RCT     | AL (artemether 20 mg-lumefantrine 200 mg) CD (chlorproguanil and dapsone) | 55   |
| Piola 2010   | Uganda                   | Open-label RCT     | QN 10 mg/kg base PO Q 8 h for 7 days AL (20/120 mg) 4 tablets at 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h for 3 days | 152  |
| Mosha 2014   | Tanzania                 | Cohort study       | AL (164), AL & QN (8), QN (70), SP (66), AQ (11) None                | 319  |
| PREGACT 2016 | Burkina Faso, Ghana, Malawi and Zambia | Open-label RCT | AL (20 mg/120 mg) 4 tablets BID for 3 days AS+AQ (100/270 mg) 2 tablets daily for 3 days DHA+PQ (40 mg/320 mg) 3 tablets daily for 3 days AS+MQ (100/220 mg) 3 tablets daily for 3 days | 880  |
| Kalilani 2007 | Malawi                   | Open-label RCT     | SP (3 tablets once; 500/25 mg) SP (3 tablets) plus AZ (1 g/day for 2 days) SP (3 tablets) plus AS (200 mg/day for 3 days) | 47   |
| Onyamboko 2020 | Congo                  | Open-label, RCT   | AL 20/120 mg tablets 4 tablets twice daily for 3 days AL 20/120 mg tablets 4 tablets twice daily for 5 days | 24   |
| McGready 2012 | Thailand                 | Prospective follow-up | CQ (429), QN (390), Artemisinin derivatives (92), MQ (32), Other or unknown (2) | 945  |
| McGready 2008 | Thailand                 | Open-label RCT     | AS7 (2 mg/kg once daily for 7 days) AL (20/120 mg): 4 tablets a day for 3 d | 128  |
| Moore 2016   | Thai–Myanmar             | Prospective follow-up | QN (971), MQ monotherapy (25), Artemisinin derivatives (185) | 1179 |

(Continued)
| Author, Year   | Country                       | Study Design                  | Treatment                                                                 | N    |
|---------------|-------------------------------|-------------------------------|---------------------------------------------------------------------------|------|
| Mutabingwa 2009<sup>27</sup> | Tanzania                      | Open-label RCT                | SP (3 tabs of 500/25 mg per tablet) orally at once                        | 28   |
|               |                               |                               | CD (1.2/2.4 mg/kg for 3 days)                                             | 81   |
|               |                               |                               | SP+AQ (SP 3 tablets once + AQ 10 mg/kg for 3 days)                        | 80   |
|               |                               |                               | AQ+AS (10/4 mg/kg for 3 days)                                             | 83   |
| Nambozi 2017<sup>27</sup>   | Zambia (part of PREGACT Study)| Open Label RCT                | AL (20/120 mg per tablet, 4 tablets twice per day over 3 days)            | 300  |
|               |                               |                               | AS+MQ (100/220 mg per tablet at 3 tabs once per day over 3 days)          | 300  |
|               |                               |                               | DHA+PQ (40/320 mg per tablet, 3 tablets once per day over 3 days)         | 300  |
| Nambozi 2019<sup>36</sup>   | Burkina Faso, Ghana, Malawi and Zambia (part of PREGACT Study) | Open Label RCT                | AL (20/120mg four tablets BID for 3 days)                                 | 822  |
|               |                               |                               | AS+AQ (100 mg/270 mg daily for 3 days)                                    | 775  |
|               |                               |                               | AS+MQ (12/24 mg/kg, 100/220 mg 3 tablets daily for three days)            | 765  |
|               |                               |                               | DHA+PQ (40/320 mg 3 tabs daily for 3 days)                                | 765  |
| Osarfo 2017<sup>23</sup>    | Ghana                         | Open-label, RCT               | AS+AQ over 3 days                                                         | 205  |
|               |                               |                               | DHA+PQ over 3 days                                                        | 212  |
| Iribhogbe 2017a<sup>23</sup> | Nigeria                       | Open-label RCT                | AS+AQ (100/270 mg) 3 tablets once daily for 3 days                        | 40   |
|               |                               |                               | AL (20/120 mg) 4 tablets twice daily for 3 days                           | 40   |
| Iribhogbe 2017<sup>24</sup>  | Nigeria                       | Non-randomized Open-label clinical trial | Non-pregnant control                                                   | 30   |
|               |                               |                               | Pregnant control                                                          | 40   |
|               |                               |                               | AS+AQ (4 and 10 mg/kg) daily for 3 days                                   | 50   |
| McGready 1998<sup>41</sup>  | Thailand                      | Prospective follow-up         | Artesunate alone                                                          | 61   |
|               |                               |                               | Artesunate + mefloquine                                                   | 26   |
|               |                               |                               | Artemether + mefloquine                                                   | 3    |
| McGready 2000<sup>14</sup>  | Thailand                      | Open-label RCT                | AS+MQ (MQ 25 mg base/kg given as 15 mg/kg on day 1 and 10 mg/kg on day 2 and AS 4 mg/kg per day in one dose on days 0, 1, and 2) | 66   |
|               |                               |                               | QN 10mg/kg base PO Q8 h for 7 days                                        | 42   |
| McGready 2003<sup>42</sup>  | Thailand                      | Prospective follow-up         | AS+ATQ+PG (artesunate 4 mg/kg/day, atovaquone (20 mg/kg/day), and proguanil) | 19   |
|               |                               |                               | AS+ATQ+PG (artesunate (2 mg/kg/day), atovaquone (20mg/kg/day), and proguanil) | 7    |
|               |                               |                               | ATQ+PG, no artesunate                                                     | 1    |
| McGready 2005<sup>40</sup>  | Thailand                      | Randomized, Open-label Clinical Trial | QN7 10 mg salt/kg every 8 h for 7 days                                    | 42   |
|               |                               |                               | AS+ATQ+PG (4/20/8mg/kg/day), each for 3 days                             | 39   |

(Continued)
Table 1 (Continued).

| Author, Year | Country     | Study Design                        | Treatment                                                                 | N  |
|--------------|-------------|-------------------------------------|---------------------------------------------------------------------------|----|
| Rulisa 2012  | Rwanda      | Cohort study                        | Exposed cohort (Pregnant women treated with AL for malaria)               | 1072 |
|              |             |                                     | Non-exposed cohort (Pregnant women without malaria)                       | 978  |
| Tarning 2009 | Thailand    | Population Pharmacokinetic Study    | AL (20/120 mg tabs twice a day for 3 days with 200–250 mL of chocolate milk containing 6–7 g of at each dose) | 103  |
| Ukah, 2015   | Nigeria     | Double-blind RCT                    | AS+AQ (100 mg/270 mg one tab twice daily for 3 days)                       | 75   |
|              |             |                                     | AL (80 mg/480 mg one tab twice daily for 3 days)                           | 75   |
| Valea 2014   | Burkina Faso| Open-label clinical trial           | Mefloquine and artesunate (pregnant women)                               | 24   |
|              |             |                                     | Mefloquine and artesunate (non-pregnant women)                            | 24   |

Abbreviations: AL, artemether-lumefantrine; AL5, artemether-lumefantrine for 5 days; AM, artemether; AM+MQ, artemether followed by mefloquine; AS+AQ, artesunate + amodiaquine; AS+ATQ+PG, artesunate + atovaquone + proguanil; AS+MQ, artesunate + mefloquine; AS+SR, artesunate + sulfadoxine-pyrimethamine; AS7, artesunate for 7 days; CD, chlorproguanil-dapsone; CQ, chloroquine; DHA+PQ, dihydroartemisinin + piperaquine; GA, gestational age; QN, quinine; QN+CL, quinine + clindamycin; RCT, randomized controlled trial; wks, weeks.

Efficacy of ACTs

Among the 24 studies, 16 reported the efficacy of ACTs in the management of malaria in pregnant women (S2 Table). Among these efficacy studies, PCR was corrected in 12 studies. Studies with PCR correction of day-28 or later cure rate were included for meta-analysis. In addition, two studies with no late treatment failure were also included in the meta-analysis (Figure 2). The detailed results observed in individual studies are given in the supplementary materials (S2 Table and S3 Table).

Artemether-Lumefantrine (AL)

There were eight studies that included AL as intervention group. The Ugandan study compared AL with quinine and reported high efficacy and the non-inferiority of AL relative to quinine. Mean fever clearance as well as parasite clearance was also comparable in a similar study in Uganda. However, a Thai study comparing AL and artesunate treatment in women with positive blood smears (AL, 125 women; AS, 128 women) reported a cure rate of less than 95% for AL at day 42 and for both treatments at delivery (or day 42 if later).

The PREGACT study in four African countries (Burkina Faso, Ghana, Malawi and Zambia) compared the efficacy of AL, AS+AQ, DHA+PQ and AS+MQ. In this study, there was no significant difference among the AS+AQ, DHA+PQ, and AS+MQ groups. However, the cure rate in the AL group was significantly lower than the rate in the other three arms.

The Congolese study compared the efficacy of a 5-day regimen of AL with the standard 3-day treatment in 48 pregnant women with uncomplicated falciparum malaria in an open-label RCT. The PCR-corrected clinical and parasitological response was 100% in both treatment arms, indicating that both the current and extended regimens of AL are highly efficacious.
### Table 2: Characteristics of Participants at Enrollment in the Studies Evaluating Efficacy and Safety of Artemisinin-Based Therapies in Pregnancy

| Author, Publication Year | Trimester     | Treatment (N)                  | Age (Year) | Weight (kg) | GA (wk) |
|--------------------------|---------------|-------------------------------|------------|-------------|---------|
| Sowunmi 1998<sup>24</sup> | 2nd and 3rd   | AM (23)                       | 29.9 (21–41) | 63.9 (50–119) |         |
|                          |               | AM+MQ (22)                    | 28.9 (20–40) | 64.1 (53–121) |         |
| Adam 2006<sup>29</sup>   | 2nd and 3rd   | AS+SP (32)                    | 29.4 ± 4.3  | 68.7 ± 12.7 | 29.7±8.4 |
| Adam 2009<sup>28</sup>   | 1st           | AM (48), AS+SP (11), AL (3)  | 27.6 [17–39] | 68.7 [48–89] | 17.5 (±3.6) [10–24] |
| Anvikar 2018<sup>38</sup>| 2nd and 3rd   | AS+SP (125)                   | 23.1 ± 3.9  | 25.5 ± 6.2  |         |
|                          |               | AS+MQ (123)                   | 23.6 ± 3.7  | 24.8 ± 5.7  |         |
| Kaye 2008<sup>30</sup>   | 2nd and 3rd   | AL (55)                       | 23.5±5.29   | 28.9±5.4    |         |
|                          |               | CD (55)                       | 23.6±5.20   | 27.3±6.3    |         |
| Piola 2010<sup>10</sup>  | 2nd and 3rd   | QN (152)                      | 22.6 (17–38)| 58 kg (10)  | 22.3 (9–38) |
|                          |               | AL (152)                      | 22.5 (15–38)| 58 kg (10)  | 24.7 (10–39) |
| Mosh 2014<sup>26</sup>   | 1st           | AL (164), AL+QN (8), QN (70), SP (66), AQ (11), None (1464) | 25.8 (13–49) | 14.8 (3–20) |         |
| PREGACT 2016<sup>35</sup>| 2nd and 3rd   | AL (880)                      | 22.6±5.6    |         |         |
|                          |               | AS+AQ (842)                   | 23.4±5.9    |         |         |
|                          |               | DHA+PQ (853)                  | 22.3±5.4    |         |         |
|                          |               | AS+MQ (848)                   | 23.5±5.9    |         |         |
| Kalilani 2007<sup>24</sup>| 2nd           | SP (47)                       | 20 (18–24)  | 53.3 (±5.9) | 22 (20–24) |
|                          |               | SP+AZ (47)                    | 20 (18–23)  | 52.2 (±6.1) | 24 (20–24) |
|                          |               | AS+SP (47)                    | 20 (17–24)  | 52.9 (±5.9) | 22 (20–24) |
| Onyamboko 2020<sup>32</sup> | 2nd and 3rd | AL (24)                      | 28.5 (±6.51) | 61.7 (±11.6) | 2nd =19.2 (±3.54) 3rd =28.9 (±4.42) |
|                          |               | AL5 (24)                      | 26.63 (±6.18) | 63.5 (±9.84) | 2nd =18.7 (±3.11) 3rd =24.9 (±5.84) |
| Mc Gready 2012<sup>13</sup> | 1st           | CQ (429), QN (390), ART (92), MQ (32), Other (2) | 26±7 (13–45) |         |         |
| Mc Gready 2008<sup>15</sup> | 2nd and 3rd | AS (128)                      | 27±8 (14–44) | 49 ±7 (3–71) | 24.8±7.6 (13.1–39.4) |
|                          |               | AL (125)                      | 26 ±7 (14–42) | 50 ±6 (35–65) | 23.7±6.8 (13.1–39.2) |
| Moore 2016<sup>39</sup>  | 1st           | QN (971), MQ (25), ART (185), | 23 (13–46)  | 8 4 [0.1–14.0] |         |
| Mutabingwa 2009<sup>37</sup> | 2nd and 3rd | SP (28)                      | 21 (19–26)  | 6 mon (5–8) |         |
|                          |               | CD (81)                       | 21 (19–27)  | 7 mon (6–8) |         |
|                          |               | SP+AQ (80)                    | 20 (19–25)  | 7 mon (5–7) |         |
|                          |               | AS+AQ (83)                    | 21 (19–26)  | 6 mon (5–7) |         |

*(Continued)*
Table 2 (Continued).

| Author, Publication Year | Trimester | Treatment (N) | Age (Year) | Weight (kg) | GA (wk) |
|--------------------------|-----------|---------------|------------|-------------|---------|
| Nambouzi 2017<sup>27</sup> | 2nd and 3rd | AL (300) | 20 (18–24) | | 2nd=50% 3rd=50% |
|                          |           | AS+MQ (300) | 19 (18–24) | | 2nd=50% 3rd=50% |
|                          |           | DHA+PQ (300) | 20 (18–24) | | 2nd=43.7% 3rd=56.3% |
| Nambouzi 2019<sup>26</sup> | 2nd and 3rd | AL (822) | 21 (18–26) | 38 (36–38) | |
|                          |           | AS+AQ (775) | 22 (19–27) | 38 (38–40) | |
|                          |           | AS+MQ (765) | 22 (19–27) | 38 (36–40) | |
|                          |           | DHA+PQ (765) | 20 (18–25) | 38 (36–38) | |
| Osarfo 2017<sup>23</sup> | 2nd and 3rd | AS+AQ (205) | | 22.3 | |
|                          |           | DHA+PQ (212) | | 22.7 | |
| Iribhogbe 2017<sup>a23</sup> | 2nd and 3rd | AS+AQ (40) | 27.2±0.51 | 68.97±0.87 | |
|                          |           | AL (40) | 31.02±0.47 | 68.23±0.25 | |
| Iribhogbe 2017<sup>24</sup> | 2nd and 3rd | Control Pregnant (30) | 26.88±0.94 | 68.12±2.04 | 27.28± 0.99 |
|                          |           | Control Non-Pregnant (40) | | | |
|                          |           | AS+AQ (50) | | | |
| McGready 1998<sup>31</sup> | 1st, 2nd and 3rd | Recrudescence infections (61) | 25 (17–38) | | 1st (18%), 2nd–3rd (82%) |
|                          |           | Hyperparasitemia (13) | 22 (1–32) | | |
|                          |           | Inadvertent exposures (16) | 29 (15–40) | | 1st (88%), 2nd–3rd (12%) |
| McGready 2000<sup>14</sup> | 2nd and 3rd | AS+MQ (66) | 24 (15–37) | 48 (36–68) | 24 (12–40) |
|                          |           | QN (42) | 23 (16–36) | 50 (41–67) | 24 (15–38) |
| McGready 2003<sup>32</sup> | 1st, 2nd and 3rd | AS+ATQ+PG (artesunate 4 mg/kg/day) (19) | 25 (16–38) | | NA | 28.2 |
|                          |           | AS+ATQ+PG (artesunate 2 mg/kg/day) (7) | | | |
|                          |           | ATQ+PG (1) | | | |
| McGready 2005<sup>50</sup> | 2nd and 3rd | QN (42) | 26±7 (16–39) | 50±7 (30–68) | 21±4.5 (14.9–30.2) |
|                          |           | AS+ATQ+PG (39) | 26±6 (16–37) | 49±7 (40–69) | 21±5.3 (10.1–36.2) |
| Rulisa 2012<sup>11</sup> | 1st, 2nd and 3rd | AL (1072) | 26.0 (17–48) | | 25.8 (95% CI: 25.3, 26.4) |
|                          |           | Non-exposed (978) | 27.0 (16–47) | | 28.5 (95% CI: 28.0, 29.0) |
| Tarning 2009<sup>43</sup> | 2nd and 3rd | AL (103) | 24 (15–42) | 49 (35–65) | 22.6 (13.1–39.0) |

(Continued)
for the treatment of uncomplicated *P. falciparum* malaria in the second and third trimester of pregnancy. The late parasitological failure observed on day 14 was 2.63% for AS+AQ and 5.41% for AL. The failure observed may be due to reinfection because there was no PCR-corrected result to rule out recrudescence.\(^{23}\) Another study from

| Author, Publication Year | Trimester | Treatment (N) | Age (Year) | Weight (kg) | GA (wk) |
|--------------------------|-----------|---------------|------------|-------------|---------|
| Ukah 2015\(^{25}\)       | 2nd and 3rd | AS+AQ (75)    | 29.2±4.8 (20–42) | 28.5±6.8 (14–40) |
|                          |           | AL (75)       | 29.4±4.6 (18–41) | 27.2±7.3 (14–40) |
| Valea 2014\(^{21}\)      | 2nd and 3rd | AS+MQ (pregnant women) (24) | 23.6±6.1 | 54.1±5.7 | 2nd trimester = 12 (50%) 3rd trimester = 12 (50%) |
|                          |           | AS+MQ (non-pregnant women) (24) | 27.0±8.9 | 53.5±5.8 |

**Note:** Bold: median (IQR).

**Abbreviations:** ACPR, adequate clinical and parasitological response; AL, artether-lumefantrine; AM, artether; AM+MQ, artether followed by mefloquine; AS +AQ, artesunate + amodiaquine; AS+ATQ+PG, artesunate + atovaquone + proguanil; AS+MQ, artesunate + mefloquine; AS+SP, artesunate + sulfadoxine-pyrimethamine; AS7, artesunate for 7 days; CD, chlorproguanil-dapsone; CQ, chloroquine; DHA+PQ, dihydroartemisinin + piperaquine; QN, quinine; QN+CL, quinine + clindamycin.

---

**Table 2** (Continued).

For the treatment of uncomplicated *P. falciparum* malaria in the second and third trimester of pregnancy. The late parasitological failure observed on day 14 was 2.63% for AS+AQ and 5.41% for AL. The failure observed may be due to reinfection because there was no PCR-corrected result to rule out recrudescence.\(^{23}\) Another study from
Nigeria, a double-blind randomized trial, was conducted to compare AS+AQ and AL combinations in the treatment of acute uncomplicated *P. falciparum* malaria during pregnancy. Unlike the other studies, the efficacy of the two treatment arms did not differ significantly in this study. High cure rates of both day-3 parasite clearance and day-28 ACPR were reported in this study.25

**Artesunate-Amodiaquine (AS+AQ)**

Six studies evaluated the efficacy of AS+AQ with other antimalarial agents. As stated above in the PREGACT study, the PCR-corrected cure rate in the AS+AQ treatment group was significantly higher than the AL treatment group.35

According to an open-label RCT study in Tanzania, pregnant women with *P. falciparum* malaria were randomized to one of the 4 regimens: SP, CD, SP+AQ or AS+AQ. PCR-corrected parasitological outcomes for AQ+AS were significantly better than for CD (AS+AQ versus CD: AOR for parasitological failure rates was 0.36, 95% CI: 0.14–0.94).27

In an open-label, randomized, non-inferiority trial in Ghana, 212 and 205 second and third trimester pregnant women, respectively, with confirmed asymptomatic *P. falciparum* parasitemia were randomized to receive DHA+PQ or AS+AQ. After controlling for age, gestational age, hemoglobin, gravidity and parasite density at enrollment, efficacy was 3.5 (95% CI: −1.5–8.5) and 3.9 (95% CI: −2.7–10.4) -fold higher by days 28 and 42, respectively, for DHA+PQ than AS+AQ. This finding brought out that DHA+PQ was non-inferior to AS+AQ for treatment of malaria infection during pregnancy, although the efficacy was not PCR corrected.33 The Nigerian studies did not also reveal a significant difference in the clinical and parasitological response between AS+AQ and AL, although PCR adjustment is lacking in both studies.23,25

**Artesunate-Mefloquine (AS+MQ)**

Five studies compared AS+MQ with other ACTs and quinine. An Indian study on pregnant women in the second or third trimester with *P. falciparum* mono-infection randomized to receive either AS+SP or AS+MQ did not show detectable difference in the probability of treatment failure between the two arms following Kaplan–Meier survival analysis.38 The PREGACT study did not also reveal significant difference in PCR-corrected cure rate among AS+AQ, DHA+PQ and AS+MQ groups.35

An open-label randomized comparison of AS+MQ versus quinine was conducted from 1995 to 1997 in 108 pregnant Thai women with acute uncomplicated *P. falciparum* malaria in the second or third trimesters of pregnancy. AS+MQ treatment arm was more effective than the quinine treatment arm as revealed by the day 63 PCR-corrected cure rates.14

**Dihydroartemisinin-Piperaquine (DHA+PQ)**

The study in four African countries (Burkina Faso, Ghana, Malawi and Zambia) showed that the cure rate in the AL group was significantly lower than the rate in the DHA+PQ treatment groups.35 The Ghanaian study indicated that the differences in efficacy (DHA+PQ versus AS+AQ) after controlling for other variables were 3.5 (95% CI: −1.5–8.5) and 3.9 (95% CI: −2.7–10.4) by days 28 and 42, respectively.33

**Meta-Analysis of Efficacy of ACTs**

Out of 16 clinical trials identified, only 13 studies were included in the meta-analysis for efficacy of ACTs in the management of uncomplicated malaria in pregnant women. Three studies were excluded (no PCR correction for “Iribhogbe 2017” and “Ukah 2015”, and no efficacy outcome for “Iribhogbe 2017a” as they do not report PCR-corrected efficacy). Overall, PCR-corrected day 28 to day 63 malaria treatment success rate for ACTs was 96.1%. However, we found high heterogeneity (overall $I^2 = 83.41%$; $p = 0.000$, 13 studies, 18 ACTs treatment groups).

Subgroup analysis was carried out to assess the heterogeneity. There were five RCTs with efficacy report of AL.10,15,25,32,35 Overall PCR-corrected cure rate was 95.1% for AL (95% CI: 91.3–98.9%; $I^2 = 89.41%$, $p < 0.001$, 5 studies) (Figure 2). AL therapy was associated with ≥95% cure rate in 3 of the 5 studies;10,30,32 the exceptions were studies from the four African countries (Burkina Faso, Ghana, Malawi and Zambia)35 and Thailand.15

There were three RCTs with efficacy report for AS+AQ.27,33,35 Overall day 28 to 63 PCR-corrected ACPR for AS+AQ was 92.2% (95% CI: 83.6–100%; $I^2 = 92.33%$, $p = 0.000$, 3 studies) (Figure 2). AS+AQ was associated with ≥95% cure rate in 1 of the 3 studies;35 but cure rates were <95% in studies from Tanzania and Ghana.33 There were four RCTs with efficacy report for AS+MQ.14,31,35,38 Overall day 28 to 63 PCR-corrected ACPR for AS+MQ was 97.0% (95% CI: 95.9–98.2%; $I^2 = 2.1%$, $p = 0.382$, 4 studies) (Figure 2). AS+MQ combination therapies were associated with ≥95% cure rates in all these studies.
There were two RCTs with efficacy report of DHA + PQ.33,35 Overall day 28 to 63 PCR-corrected ACPR for DHA+PQ was 94.92% (95% CI: 84.3–104.3%; I² = 94.92%, p<0.000, 2 studies) (Figure 2). DHA+PQ combination therapy was associated with ≥95% cure rate in 1 of the 2 studies;35 the exception was the study from Ghana.33

There were two RCTs with efficacy report of AS+ATQ + PG.40,42 Overall day 28 to 63 PCR-corrected ACPR for AS + ATQ+PG was 96.5% (95% CI: 91.8–101.1%; I² = 0.0%, p<0.548, 2 studies) (Figure 2). AS+ATQ+PG combination therapies were associated with ≥95% cure rates in both of these studies.

There were two RCTs with efficacy report of AS + SP.29,38 Overall day 28 to 63 PCR-corrected ACPR for AS + SP was 97.4% (95% CI: 94.3–102.7%; I² = 0.0%, p<0.524, 2 studies) (Figure 2). AS+SP combination therapies were associated with ≥95% cure rates in both of these studies. The limited number of available studies with PCR-corrected outcome comparing different ACTs precluded aggregate data meta-analysis.

PCR-Corrected ACPR Comparison of Different Treatments

In the five RCTs that were included for meta-analysis to compare ACTs and non-ACTs, the risk of treatment failure was substantially lower in patients treated with ACTs than in patients treated with non-ACTs (risk ratio 0.20, 95% CI: 0.09–0.43) (Figure 3), although the compared treatments and methodologies differed.

Safety of ACTs

The safety of AL and quinine was recently compared in an open-label randomized non-inferiority trial in Uganda on second and third trimester pregnant women with uncomplicated *Plasmodium falciparum* malaria treated with either AL (152) or quinine (152). No significant differences were observed between the treatment arms in the frequency of miscarriages, stillbirths, early neonatal deaths, malformations, prematurity and low birth weight.10

Between 2006 and 2008, an observational study investigated the safety of artemisinins including artemether injection, AS+SP and AL in the first trimester of pregnancy in...
Sudan. There was no congenital abnormality documented, but miscarriage occurred in two women who were treated with artemether injection in the first trimester while quinine infusion was administered for a subsequent malaria attack.28

Between April 2004 and August 2006, the safety of AL and artemunate was compared in an open-label RCT in the second and third trimesters of pregnancy in Thailand.15 Pregnant women with acute \textit{P. falciparum} malaria were allocated to AL and artemunate treatment groups. There was no significant birth outcome difference in the two treatment groups. But death rates were significantly more in the artemunate group (6.7%) than the AL group (0.9%), although these deaths were unrelated to the treatments received.15

In an observational cohort study conducted in Tanzania in pregnant women in the first trimester, 1783 (82.3%) women completed the study until delivery. Out of them, 319 (17.9%) used antimalarial drugs in the first trimester, of whom 172 were on AL, 78 on QN, 66 on SP and 11 on AQ. Analysis showed that first trimester exposure of quinine was associated with a two-fold increased risk of miscarriage, stillbirth and preterm birth compared with the other treatments.26

In the PREGACT study, there were no significant difference in the proportion of live births among the treatment arms. The average birth weight and the incidence of miscarriages, stillbirths, preterm deliveries, and malformations were similar among the treatment arms.35

In the Rwandan prospective cohort study from June 2007–July 2009, exposed group (pregnant women with malaria given AL), and a matched non-exposed group (pregnant women without malaria and not exposed to AL) were followed until delivery. The authors noted that the rates of abortion, perinatal mortality, stillbirth and premature delivery were slightly increased in the treatment group and argued that this was probably due to the acute complications of malaria itself instead of the interventions given.11

The Indian study that compared AS+SP and AS+MQ reported that low birth weight (< 2.5 kg) was significantly higher in the AS+SP than in the AS+MQ treatment group, however, there was no statistically significant difference in miscarriages, preterm delivery or stillbirths between the treatment arms.38

In the Malawian randomized clinical trial, pregnant women with uncomplicated \textit{P. falciparum} malaria were allocated in three treatment arms: 47 women in each of the treatment arms (SP only, SP + Azithromycin and AS +SP). The authors indicated that the observed abortions, stillbirths and neonatal deaths potentially had other proximal causes than directly related to the interventions provided.34

The observational study in the Thai–Burmese border analyzed antenatal register of pregnant women exposed to chloroquine-based, quinine-based or artemisinin-based treatments in the first trimester. The risk of miscarriage and stillbirth was similar in all groups. Congenital anomaly also similarly occurred among babies born from women treated with chloroquine, quinine or artemunate.13

In the Tanzanian study from January 2004–September 2006, pregnant women with uncomplicated \textit{P. falciparum} malaria were allocated in four treatment arms: SP, CD, SP +AQ or AQ+AS. In this trial there was no report of apparent excess stillbirths or adverse birth outcomes in any of the arms.27

Low birth weight was significantly higher in the DHA +PQ arm as compared with AS+AQ in the Ghanaian study. Furthermore, two cases each of neonatal deaths and stillbirths were recorded in the DHA+PQ arm, while one case of stillbirth was observed in the AS+AQ arm. The authors argued that the higher prevalence of low birth weight in the DHA+PQ arm could be attributed to a chance finding not attributable to DHA+PQ.33

In a study from Thailand comparing the safety of QN and AS+ATQ+PG, there was no significant difference in mean birth weight, baby growth parameters and estimated gestational age (EGA) or in the proportion of low birth weight, premature, or intrauterine growth–retarded infants. Identified congenital abnormalities were considered unlikely to be drug related.40

Meta-Analysis of Pregnancy Outcomes

Miscarriage

Seven studies reported a total of 20 miscarriages among 3996 women who received ACTs during pregnancy. The overall prevalence was 0.3% and found to be similar among various ACTs (0.1% for AL, 0.5% for AS+AQ, DHA+PQ and AS+MQ) (S1 Figure).

Stillbirth

Six studies reported a total of 90 stillbirths among 3927 women who received ACTs during pregnancy. The overall prevalence of stillbirth was 2.1% and found to be similar among various ACTs (1.7% for AL, 1.9% for AS+AQ, 2.8% for AS+MQ and 2.5% for DHA+PQ) (S2 Figure).
Low Birth Weight
Nine studies reported a total of 603 low birthweight newborns among 3891 women who received ACTs during pregnancy. The overall prevalence of low birthweight was 14.2% and found to be higher for AS+SP (23.6%) but it was relatively similar among the other ACTs (16.3% for AS+MQ, 14.4% for DHA+PQ, 12.6% for AL and 10.2% for AS+AQ) (S3 Figure).

Congenital Anomalies
Six studies reported a total of 43 congenital anomalies among 3973 women who received ACTs during pregnancy. The overall prevalence of congenital anomalies was 1.0% and found to be similar among the ACTs (1.5% for DHA+PQ, 0.9% for AS+AQ and 1.2% for AL) (S4 Figure).

Tolerability of ACTs
According to the Thailand study,15 tolerability of AL and AS treatments was similar. Hematology, blood chemistry and ECG evaluations detected no difference in the occurrence of abnormal values. However, tinnitus was significantly different in the two treatment groups (AL, 0%; AS, 8.5%).

The PREGACT study in four African countries indicated that there was no significant difference in the occurrence of serious adverse events among the treatment arms.35 Among these severe adverse events, severe vomiting associated with the AS+MQ arm was considered to be related to the study treatment.37 The Ghanaian trial of AS +AQ and DHA+PQ documented severe diarrhea associated with AS+AQ, which was thought to be related to the treatment.33 Other trials, including RCTs, comparing ACT with other ACTs or other antimalarial agents reported no treatment-related severe adverse events in India,38 Malawi,34 Nigeria34 and Thailand.14,40

Tinnitus was one of the common adverse events reported in these trials. It was largely noted with treatment of QN as revealed by the Ugandan (QN versus AL),10 and Thailand studies (AS+MQ versus QN)14 and (QN versus AS+ATQ+PG).40 In a comparative study of AL and AS7 conducted in Thailand, tinnitus was once again the only symptom that significantly differed between the treatment arms, which was more frequent in the AS7 arm (8.5%).15

Headache, dizziness, nausea, vomiting, poor appetite and asthenia were the other common treatment-related adverse events reported by these trials. In the PREGACT trial conducted in four African countries, significantly higher rate of treatment-related adverse events occurred in the AS+MQ group and the AS+AQ group than in the DHA+PQ group and the AL group.35 Other studies also demonstrated that a higher rate of dizziness was noted in the QN than the AS+MQ arm.14 Vomiting was significantly higher in the AS+MQ than the AS+SP treatment arm in the Indian study.38 Whilst women in the quinine arm had more frequent adverse events, such as nausea, vomiting, and anorexia than AL group, headache was higher in AL group in the Ugandan study.10

Risk of Bias Across Studies
Fifteen clinical trials were evaluated using a revised tool for assessing risk of bias in randomized trials (ROB 2),18 while the other eight studies were assessed with the STROBE statement.19 Two clinical trials were found to have low risk of bias and all observational studies were judged to have high quality (S4 Table).

Discussion
Systematic review and meta-analysis was conducted to compile and synthesize comprehensive evidence on efficacy and safety of ACT use for treatment of uncomplicated malaria during pregnancy. The overall ACPR of the ACTs was more than 95%, which is in line with WHO recommendations. Except for three treatment arms: AL,15 AS+AQ33 and DHA +PQ,33 all the ACT treatment arms had an ACPR of greater than 90% at day 28 or greater follow-up. The WHO recommends a change in the treatment regimen if the treatment failure of an ACT is greater than or equal to 10%.20

In the five RCTs that were included for meta-analysis to compare ACTs and non-ACTs, the risk of treatment failure was substantially lower in patients treated with ACTs than in patients treated with non-ACTs (risk ratio 0.20, 95% C.I. 0.09–0.43). Similar findings were reported in a meta-analysis that compared ACTs with quinine-based therapies (risk ratio 0.22, 95% C.I. 0.07–0.63).45

This review revealed that the overall efficacy of AL in pregnant women was greater than 95% with meta-analysis of five trials. Despite this, it was reported that the cure rate in AL treatment group was significantly lower compared with AS+AQ, AS+MQ and DHA+PQ.35 In one trial a less than 90% cure rate of AL was reported in pregnant patients.15 This could have resulted from the lower drug concentrations achieved by both artemether and lumefantrine.46,47 Indeed, an Ugandan study demonstrated that pregnant women had a 27% lower plasma concentration of lumefantrine than non-pregnant women.48
According to this review, the overall efficacy of AS + AQ was greater than 90% with the meta-analysis of three of the studies included in this review. One of the trials indicated that AS+AQ had significantly greater cure rate than CD.  

Previous pharmacokinetic studies on pregnant women in Thailand showed that increasing the usual dose of proguanil was mandatory to achieve comparable plasma drug concentrations. Findings of a study indicated the equivalence of AS+AQ efficacy with DHA+PQ.  

The overall efficacy of AS+MQ was shown to be 97.0% (95% C.I. 95.9–98.2%), which is greater than 95% with the meta-analysis of four studies included in this review. Studies included in this trial indicated that the efficacy of AS+MQ is comparable with AS+SP, DHA+PQ, AS+AQ but significantly greater than the cure rate of AL and quinine.  

The overall ACPR for DHA+PQ was 94.3% (95% C.I. 84.3–104.3%). Studies included in this trial indicated that the efficacy of DHA+PQ is comparable with AS+AQ, AS+MQ but significantly greater than the cure rate of AL. The overall day-28 or greater ACPR of AS+ATQ +PG and AS+SP was greater than 95%.  

Trials showed that AL could grant the shortest-range post-treatment preventive activity against malaria as compared with the other ACTs. In the PREGACT study, reinfection rate was the highest in patients managed with AL and time to reinfection was the shortest in this treatment group. One of the crucial factors in the choice of drugs for malaria management is the duration of post-treatment prophylaxis, particularly in regions with a high probability of infection. It was found that lumefantrine has a rapid clearance, followed by amodiaquine, mefloquine, and then piperaquine.  

In this review, there were 607 pregnant women exposed to artemisinin treatment in the first trimester of pregnancy, as reported by observational studies in Sudan, Tanzania, Thailand, Thai-Myanmar, and Rwanda. Data on cure rates in the first trimester were only available from observational studies, which posed difficulty to compare the outcomes using aggregated evidences. On top of this, the findings were rarely sorted by trimester, and the assessment of gestational age varied among the studies.  

With the available observational studies, the risk of birth outcomes was not found to be higher in women taking ACTs in the first trimester. There was no significant birth outcome difference including miscarriage, stillbirth, early neonatal deaths, malformations, prematurity, low birth weight in various trials comparing combination of the various treatment groups. Observational studies in the antenatal registers of pregnant women in the first trimester could not also demonstrate the risk of adverse birth outcomes associated with ACTs. From 62 women who received ACTs (including artesether injection, AS+SP and AL) in the first trimester of pregnancy, there was no maternal mortality reported and all newborns were delivered at full term, with no congenital abnormalities. By contrast, first trimester exposure of quinine was associated with an increased risk of miscarriage and stillbirth in the Tanzanian observational cohort study and abortive effect of quinine was linked to induction of uterine contractions. Moreover, the Ugandan study also revealed that oral quinine had nearly two-fold increase in intrauterine fetal deaths than the AL group among women in the second and third trimesters of pregnancy.  

The Indian study that compared AS+SP and AS+MQ reported that miscarriages, preterm delivery or stillbirths were similar in treatment arms but low birth weight (< 2.5 kg) was reported to be higher in the AS+SP treatment group (28.1%) than in the AS+MQ treatment group (16.7%). Higher proportion of low birth weight was not reported in other studies. In the Ghanaian trial comparing DHA+PQ and AS+AQ in pregnant women, low birth weight was observed in 9.3% of babies and was higher in the DHA+PQ arm compared with AS+AQ (13.2% versus 4.2%). This finding was not consistent with other studies using DHA+PQ for treatment or prevention of malaria in pregnancy.  

Trials comparing ACT with other ACTs or other anti-malarial agents reported no treatment-related severe adverse events including RCTs in India, Malawi, Nigeria and Thailand. Although 10 severe adverse events were reported in the PREGACT study, there was no significant difference in the occurrence of severe adverse events among the treatment arms. Tinnitus was dominantly reported with pregnant women who took quinine than ACTs or other anti-malarial drugs. Other adverse events including dizziness, headache, nausea, vomiting, poor appetite and asthenia occurred significantly
at higher rates in the AS+MQ and AS+MQ groups in the PREGACT study.35

Even though this review generated comprehensive evidence on efficacy and safety of ACTs in pregnant women, it was subject to some limitations. The studies included were heterogeneous in design. Each study used a different ACT, and the timing of the measurement of the primary efficacy endpoint, the PCR-corrected failure rate varied from days 28 to 63. Indicators for tolerability differed among studies as well as the methods and timing of assessment of many of the secondary efficacy endpoints varied, which made it difficult to pool the information. The number of studies and study participants were limited, and data for studies with first trimester exposure of ACTs were compiled only from observational studies (not RCTs). This may limit the generalizability of the findings.

**Conclusion**

Meta-analysis of available evidence indicated that ACTs demonstrated high overall efficacy for treatment of uncomplicated falciparum malaria (96.1%). Overall days 28 to 63 cure rates for AL, AS+AQ, AS+MQ, DHA+PQ, AS+ATQ+PG and AS+SP were 95.1%, 92.2%, 97.0%, 94.3%, 96.5% and 97.4%, respectively. Analysis of treatment failure among ACTs and non-ACTs indicated that risk of treatment failure at days 28 to 63 cure rate was significantly lower in patients treated with ACTs than in patients treated with non-ACTs. Adverse birth outcomes were comparable among ACTs and the risks of pregnancy and neonatal outcomes, and other adverse events were not found to be higher in women taking ACT, supporting the use of ACTs during pregnancy. As evidenced by data from observational studies, first trimester exposure of ACTs was not found to be associated with an increased risk of adverse birth outcomes.

**Abbreviations**

ACPR, Adequate clinical and parasitological response; AL, Artemether–lumefantrine; AS+AQ, Artesunate + amodiaquine; AS+ATQ+PG, Artesunate + atovaquone + proguanil; AS+MQ, Artesunate + mefloquine; AS+SP, Artesunate + sulfadoxine-pyrimethamine; DHA+PQ, Dihydroartemisinin + piperaquine; MeSH, Medical subject heading; PICOS, Population, intervention, comparison, outcome, study; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

**Data Sharing Statement**

The datasets used during the current study are presented within the manuscript and/or additional supporting files, and also available from the corresponding author on reasonable request.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This work is supported by a grant from European and Developing Countries Clinical Trials Partnership (EDCTP) and European Union (Grant number:TMA2016IF-1778).

**Disclosure**

The authors declare that there is not any real or perceived conflict of interest.

**References**

1. World Health Organization. World Malaria Report 2020: 20 Years of Global Progress and Challenges. Geneva: World Health Organization; 2020.
2. Desai M, Ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. *Lancet Infect Dis*. 2007;7(2):93–104. doi:10.1016/S1473-3099(07)70021-X
3. Nosten F, McGeary R, d’Alessandro U, et al. Antimalarial drugs in pregnancy: a review. *Curr Drug Saf*. 2006;1(1):1–15. doi:10.2174/157488606775252584
4. White NJ, McGready RM, Nosten FH. New medicines for tropical diseases in pregnancy: catch-22. *PLoS Med*. 2008;5(6):e133. doi:10.1371/journal.pmed.0050133
5. World Health Organization. *Artemisinin Resistance and Artemisinin-Based Combination Therapy Efficacy: Status Report*. World Health Organization; 2018.
6. World Health Organization. 2001. Antimalarial drug combination therapy. Report of a WHO technical consultation: 1–35.
7. World Health Organization. *Guidelines for the Treatment of Malaria*. World Health Organization; 2015.
8. WHO Malaria Policy Advisory Committee, Secretariat. Malaria policy advisory committee to the WHO: conclusions and recommendations of September 2012 meeting. *Malar J*. 2012;11(1):424. doi:10.1186/1475-2875-11-424
9. Chaabane S, Bérard A. Epidemiology of major congenital malformations with specific focus on teratogens. *Curr Drug Saf*. 2013;8(2):128–140. doi:10.2174/15748863112079990011
10. Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. *Lancet Infect Dis*. 2010;10(11):762–769. doi:10.1016/S1473-3099(10)70202-4
44. Sowunmi A, Oduuola A, Ogundahunsi O, et al. Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sulfadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. *J Obstet Gynaecol*. 1998;18(4):322–327. doi:10.1080/01443619867038

45. Saito M, Gilder ME, Nosten F, McGready R, Guérin PJ. Systematic literature review and meta-analysis of the efficacy of artesiminin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges. *Malar J*. 2017;16:1–17. doi:10.1186/s12936-016-1500-6

46. McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. *Eur J Clin Pharmacol*. 2006;62(12):1021. doi:10.1007/s00228-006-0199-7

47. McGready R, Stepniewska K, Ward S, et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. *Eur J Clin Pharmacol*. 2006;62(5):367–371. doi:10.1007/s00228-006-0118-y

48. Kloprogge F, Piola P, Dhorda M, et al. Population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. *Malar J*. 2012;11(1):398. doi:10.1186/1475-2875-11-398

49. Wangboonskul J, White N, Nosten F, Ter Kuile F, Moody R, Taylor R. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. *Eur J Clin Pharmacol*. 1993;44(3):247–251. doi:10.1007/BF00271366

50. Valley A, Valley L, Changalucha J, Greenwood B, Chandramohan D. Intermittent preventive treatment for malaria in pregnancy in Africa: what’s new, what’s needed? *Malar J*. 2007;6(1):16. doi:10.1186/1475-2875-6-16

51. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. *Lancet Infect Dis*. 2010;10(6):405–416. doi:10.1016/S1473-3099(10)70079-7

52. Rijken MJ, McGready R, Jullien V, et al. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. *Antimicrob Agents Chemother*. 2011;55(9):4338–4342. doi:10.1128/AAC.00154-11

53. Hoglund RM, Adam I, Hanphithakpong W, et al. A population pharmacokinetic model of piperazine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. *Malar J*. 2012;11(1):398. doi:10.1186/1475-2875-11-398

54. Preston Maxwell DJ. The use of quinine during pregnancy, labour, and the puerperium. *Trans R Soc Trop Med Hyg*. 1998;12:229–235. doi:10.1016/S0035-9203(07)90031-0

55. Desai M, Gutterman J, Llanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin–piperazine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. *The Lancet*. 2015;386:2507–2519.

56. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin–piperazine for the prevention of malaria in pregnancy. *N Engl J Med*. 2016;374(10):928–939. doi:10.1056/NEJMoa1509150

57. Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin—Piperazine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. *Am J Trop Med Hyg*. 2008;78:543–545. doi:10.4269/ajtmh.2008.78.543

**Therapeutics and Clinical Risk Management**

**Publish your work in this journal**

**Therapeutics and Clinical Risk Management** is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal